1. Home
  2. CHE vs GRFS Comparison

CHE vs GRFS Comparison

Compare CHE & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CHE

Chemed Corp

HOLD

Current Price

$451.92

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$8.87

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHE
GRFS
Founded
1970
1940
Country
United States
Spain
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2B
6.2B
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
CHE
GRFS
Price
$451.92
$8.87
Analyst Decision
Strong Buy
Hold
Analyst Count
4
2
Target Price
$574.25
$10.15
AVG Volume (30 Days)
139.1K
485.7K
Earning Date
02-25-2026
07-28-2022
Dividend Yield
0.53%
1.60%
EPS Growth
N/A
N/A
EPS
18.95
0.64
Revenue
$2,530,634,000.00
$8,821,017,248.00
Revenue This Year
$5.91
$5.36
Revenue Next Year
$6.21
$5.15
P/E Ratio
$23.85
$17.46
Revenue Growth
6.45
7.31
52 Week Low
$408.42
$6.19
52 Week High
$623.61
$11.14

Technical Indicators

Market Signals
Indicator
CHE
GRFS
Relative Strength Index (RSI) 59.42 44.66
Support Level $438.87 $8.79
Resistance Level $459.55 $9.40
Average True Range (ATR) 10.16 0.24
MACD 2.08 -0.05
Stochastic Oscillator 77.47 12.18

Price Performance

Historical Comparison
CHE
GRFS

About CHE Chemed Corp

Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. Through its subsidiaries, the company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: